D
Lexaria Bioscience Corp.
LEXX
$1.35
$0.032.27%
D
Sell
2/21/2025Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 2/21/2025 due to an increase in the volatility index and valuation index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 2/21/2025 due to an increase in the volatility index and valuation index.
E
Sell
2/5/2025Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 2/5/2025 due to a decline in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 2/5/2025 due to a decline in the volatility index and total return index.
D
Sell
1/21/2025Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 1/21/2025 due to an increase in the growth index, valuation index and solvency index. The quick ratio increased from 6.1 to 28.15, and total revenue increased 118.93% from $84 to $183.9.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 1/21/2025 due to an increase in the growth index, valuation index and solvency index. The quick ratio increased from 6.1 to 28.15, and total revenue increased 118.93% from $84 to $183.9.
E
Sell
11/29/2024Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 11/29/2024 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 55.84 to 6.1.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 11/29/2024 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 55.84 to 6.1.
D
Sell
7/15/2024Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 7/15/2024 due to an increase in the valuation index, total return index and solvency index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 7/15/2024 due to an increase in the valuation index, total return index and solvency index.
E
Sell
5/3/2024Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 5/3/2024 due to a decline in the valuation index and growth index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 5/3/2024 due to a decline in the valuation index and growth index.
D
Sell
4/18/2024Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 4/18/2024 due to a large increase in the solvency index, total return index and growth index. The quick ratio increased from 20.57 to 63.02, debt to equity declined from 0.01 to 0, and earnings per share increased from -$0.1303 to -$0.0603.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 4/18/2024 due to a large increase in the solvency index, total return index and growth index. The quick ratio increased from 20.57 to 63.02, debt to equity declined from 0.01 to 0, and earnings per share increased from -$0.1303 to -$0.0603.
E
Sell
2/16/2024Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 2/16/2024 due to a decline in the valuation index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 2/16/2024 due to a decline in the valuation index.
D
Sell
2/1/2024Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 2/1/2024 due to an increase in the volatility index, solvency index and total return index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 2/1/2024 due to an increase in the volatility index, solvency index and total return index.
E
Sell
1/16/2024Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 1/16/2024 due to a decline in the valuation index and volatility index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 1/16/2024 due to a decline in the valuation index and volatility index.
D
Sell
1/5/2024Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 1/5/2024 due to an increase in the total return index and volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 1/5/2024 due to an increase in the total return index and volatility index.
E
Sell
11/22/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 11/22/2023 due to a decline in the volatility index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 11/22/2023 due to a decline in the volatility index.
D
Sell
11/7/2023Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 11/7/2023 due to an increase in the volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 11/7/2023 due to an increase in the volatility index.
E
Sell
5/17/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 5/17/2023 due to a decline in the total return index and volatility index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 5/17/2023 due to a decline in the total return index and volatility index.
D
Sell
5/2/2023Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 5/2/2023 due to an increase in the volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 5/2/2023 due to an increase in the volatility index.
E
Sell
4/17/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 4/17/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 18.08 to 16.48.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 4/17/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 18.08 to 16.48.
D
Sell
4/3/2023Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index.
E
Sell
3/16/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 03/16/2023.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 03/16/2023.
D
Sell
3/3/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 3/3/2023 due to a decline in the volatility index.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 3/3/2023 due to a decline in the volatility index.
D
Sell
2/10/2023Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/7/2023Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 2/7/2023 due to an increase in the total return index and volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 2/7/2023 due to an increase in the total return index and volatility index.
D
Sell
1/19/2023Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 1/19/2023 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 32.79 to 18.08, earnings per share declined from -$0.2466 to -$0.2951, and EBIT declined 16.92% from -$1.51M to -$1.77M.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 1/19/2023 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 32.79 to 18.08, earnings per share declined from -$0.2466 to -$0.2951, and EBIT declined 16.92% from -$1.51M to -$1.77M.
D
Sell
11/29/2022Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 11/29/2022 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.4004 to -$0.2466, EBIT increased 37.43% from -$2.42M to -$1.51M, and total revenue increased 11.53% from $99.7 to $111.2.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 11/29/2022 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.4004 to -$0.2466, EBIT increased 37.43% from -$2.42M to -$1.51M, and total revenue increased 11.53% from $99.7 to $111.2.
D
Sell
8/29/2022Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 8/29/2022 due to an increase in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 8/29/2022 due to an increase in the volatility index and total return index.
E
Sell
7/15/2022Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 7/15/2022 due to a large decline in the growth index, total return index and solvency index. EBIT declined 66.93% from -$1.45M to -$2.42M, earnings per share declined from -$0.2412 to -$0.4004, and the quick ratio declined from 56.89 to 36.23.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 7/15/2022 due to a large decline in the growth index, total return index and solvency index. EBIT declined 66.93% from -$1.45M to -$2.42M, earnings per share declined from -$0.2412 to -$0.4004, and the quick ratio declined from 56.89 to 36.23.
D
Sell
5/5/2022Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
1/14/2022Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 1/14/2022 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.2183 to -$0.35, total revenue declined 55.16% from $31 to $13.9, and EBIT declined 25.05% from -$1.6M to -$2M.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 1/14/2022 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.2183 to -$0.35, total revenue declined 55.16% from $31 to $13.9, and EBIT declined 25.05% from -$1.6M to -$2M.
D
Sell
11/30/2021Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 11/30/2021 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.5009 to -$0.2183, EBIT increased 32.17% from -$2.36M to -$1.6M, and operating cash flow increased 0.47% from -$1.17M to -$1.16M.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 11/30/2021 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.5009 to -$0.2183, EBIT increased 32.17% from -$2.36M to -$1.6M, and operating cash flow increased 0.47% from -$1.17M to -$1.16M.
D
Sell
11/24/2021Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 11/24/2021 due to a decline in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 11/24/2021 due to a decline in the volatility index and total return index.
D
Sell
11/9/2021Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
Lexaria Bioscience Corp. (LEXX) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
D
Sell
11/3/2021Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index and total return index.
D
Sell
10/8/2021Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 10/8/2021 due to an increase in the volatility index and total return index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 10/8/2021 due to an increase in the volatility index and total return index.
D
Sell
9/22/2021Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 9/22/2021 due to a decline in the volatility index.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 9/22/2021 due to a decline in the volatility index.
D
Sell
9/3/2021Upgraded
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 9/3/2021 due to an increase in the volatility index, total return index and valuation index.
Lexaria Bioscience Corp. (LEXX) was upgraded to D from D- on 9/3/2021 due to an increase in the volatility index, total return index and valuation index.
D
Sell
7/16/2021Downgrade
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 7/16/2021 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0997 to -$0.5009, EBIT declined 131.82% from -$1.02M to -$2.36M, and operating cash flow declined 30.16% from -$897.1 to -$1.17M.
Lexaria Bioscience Corp. (LEXX) was downgraded to D- from D on 7/16/2021 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0997 to -$0.5009, EBIT declined 131.82% from -$1.02M to -$2.36M, and operating cash flow declined 30.16% from -$897.1 to -$1.17M.
D
Sell
5/1/2020Upgraded
Lexaria Bioscience Corp. (LXRP) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index and valuation index. Total revenue increased 72.79% from $62.1 to $107.3.
Lexaria Bioscience Corp. (LXRP) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index and valuation index. Total revenue increased 72.79% from $62.1 to $107.3.
D
Sell
1/11/2019Downgrade
Lexaria Bioscience Corp. (LXRP) was downgraded to D- from D on 1/11/2019 due to a significant decline in the total return index and volatility index.
Lexaria Bioscience Corp. (LXRP) was downgraded to D- from D on 1/11/2019 due to a significant decline in the total return index and volatility index.
D
Sell
7/16/2018Upgraded
Lexaria Bioscience Corp. (LXRP) was upgraded to D from D- on 7/16/2018 due to a large increase in the total return index.
Lexaria Bioscience Corp. (LXRP) was upgraded to D from D- on 7/16/2018 due to a large increase in the total return index.
D
Sell
4/13/2018Downgrade
Lexaria Bioscience Corp. (LXRP) was downgraded to D- from D on 4/13/2018 due to a significant decline in the total return index, growth index and efficiency index. EBIT declined 141.34% from -$572.8 to -$1.38M, net income declined 138.19% from -$578.7 to -$1.38M, and earnings per share declined from -$0.0084 to -$0.02.
Lexaria Bioscience Corp. (LXRP) was downgraded to D- from D on 4/13/2018 due to a significant decline in the total return index, growth index and efficiency index. EBIT declined 141.34% from -$572.8 to -$1.38M, net income declined 138.19% from -$578.7 to -$1.38M, and earnings per share declined from -$0.0084 to -$0.02.
D
Sell
1/12/2018Downgrade
Lexaria Bioscience Corp. (LXRP) was downgraded to D from D+ on 1/12/2018 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 27.92 to 23.84, and total capital declined 13.23% from $2.77M to $2.4M.
Lexaria Bioscience Corp. (LXRP) was downgraded to D from D+ on 1/12/2018 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 27.92 to 23.84, and total capital declined 13.23% from $2.77M to $2.4M.
D
Sell
11/28/2017Upgraded
Lexaria Bioscience Corp. (LXRP) was upgraded to D+ from D on 11/28/2017 due to a substantial increase in the solvency index, efficiency index and total return index. Debt to equity declined from 0.01 to 0.
Lexaria Bioscience Corp. (LXRP) was upgraded to D+ from D on 11/28/2017 due to a substantial increase in the solvency index, efficiency index and total return index. Debt to equity declined from 0.01 to 0.
D
Sell
4/17/2017Upgraded
Lexaria Bioscience Corp. (LXRP) was upgraded to D from E+ on 4/17/2017 due to a noticeable increase in the solvency index, total return index and volatility index.
Lexaria Bioscience Corp. (LXRP) was upgraded to D from E+ on 4/17/2017 due to a noticeable increase in the solvency index, total return index and volatility index.
E
Sell
11/29/2016Downgrade
Lexaria Bioscience Corp. (LXRP) was downgraded to E+ from D+ on 11/29/2016 due to a large decline in the growth index, efficiency index and solvency index. Operating cash flow declined 140.81% from -$108.3 to -$260.8, earnings per share declined from -$0.0057 to -$0.0089, and net income declined 21.86% from -$258 to -$314.4.
Lexaria Bioscience Corp. (LXRP) was downgraded to E+ from D+ on 11/29/2016 due to a large decline in the growth index, efficiency index and solvency index. Operating cash flow declined 140.81% from -$108.3 to -$260.8, earnings per share declined from -$0.0057 to -$0.0089, and net income declined 21.86% from -$258 to -$314.4.
D
Sell
10/28/2016Upgraded
Lexaria Bioscience Corp. (LXRP) was upgraded to D+ from D on 10/28/2016 due to an increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.0059 to -$0.0057, and net income increased 0.69% from -$259.8 to -$258.
Lexaria Bioscience Corp. (LXRP) was upgraded to D+ from D on 10/28/2016 due to an increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.0059 to -$0.0057, and net income increased 0.69% from -$259.8 to -$258.
D
Sell
3/11/2016Downgrade
Lexaria Corp. (LXRP) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
Lexaria Corp. (LXRP) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
C
Hold
3/7/2016Upgraded
Lexaria Corp. (LXRP) was upgraded to C- from D+ on 3/7/2016 due to a significant increase in the volatility index.
Lexaria Corp. (LXRP) was upgraded to C- from D+ on 3/7/2016 due to a significant increase in the volatility index.
D
Sell
1/25/2016Downgrade
Lexaria Corp. (LXRP) was downgraded to D+ from C- on 1/25/2016 due to a significant decline in the volatility index, solvency index and total return index.
Lexaria Corp. (LXRP) was downgraded to D+ from C- on 1/25/2016 due to a significant decline in the volatility index, solvency index and total return index.
C
Hold
1/8/2016Upgraded
Lexaria Corp. (LXRPD) was upgraded to C- from D on 1/8/2016 due to a significant increase in the volatility index, solvency index and total return index.
Lexaria Corp. (LXRPD) was upgraded to C- from D on 1/8/2016 due to a significant increase in the volatility index, solvency index and total return index.
D
Sell
1/16/2015Downgrade
Lexaria Corp. (LXRP) was downgraded to D from D+ on 1/16/2015 due to a noticeable decline in the efficiency index, solvency index and valuation index. Total capital declined 66.44% from $4.36M to $1.46M, net income declined 39.76% from -$576.4 to -$347.2, and the quick ratio declined from 0.71 to 0.64.
Lexaria Corp. (LXRP) was downgraded to D from D+ on 1/16/2015 due to a noticeable decline in the efficiency index, solvency index and valuation index. Total capital declined 66.44% from $4.36M to $1.46M, net income declined 39.76% from -$576.4 to -$347.2, and the quick ratio declined from 0.71 to 0.64.
D
Sell
12/17/2014Upgraded
Lexaria Corp. (LXRP) was upgraded to D+ from D on 12/17/2014 due to an increase in the growth index and total return index.
Lexaria Corp. (LXRP) was upgraded to D+ from D on 12/17/2014 due to an increase in the growth index and total return index.
D
Sell
10/7/2014Downgrade
Lexaria Corp. (LXRP) was downgraded to D from D+ on 10/7/2014 due to a substantial decline in the volatility index and total return index.
Lexaria Corp. (LXRP) was downgraded to D from D+ on 10/7/2014 due to a substantial decline in the volatility index and total return index.
D
Sell
9/12/2014Downgrade
Lexaria Corp. (LXRP) was downgraded to D+ from C- on 9/12/2014 due to a major decline in the growth index, total return index and efficiency index. Total revenue declined 19.01% from $167.8 to $135.9, total capital declined 6.18% from $4.64M to $4.36M, and earnings per share declined from -$0.0206 to -$0.02.
Lexaria Corp. (LXRP) was downgraded to D+ from C- on 9/12/2014 due to a major decline in the growth index, total return index and efficiency index. Total revenue declined 19.01% from $167.8 to $135.9, total capital declined 6.18% from $4.64M to $4.36M, and earnings per share declined from -$0.0206 to -$0.02.
C
Hold
5/16/2014Downgrade
Lexaria Corp. (LXRP) was downgraded to C- from C on 5/16/2014 due to a decline in the total return index.
Lexaria Corp. (LXRP) was downgraded to C- from C on 5/16/2014 due to a decline in the total return index.
C
Hold
4/28/2014Upgraded
Lexaria Corp. (LXRP) was upgraded to C from C- on 4/28/2014 due to a noticeable increase in the total return index, valuation index and volatility index.
Lexaria Corp. (LXRP) was upgraded to C from C- on 4/28/2014 due to a noticeable increase in the total return index, valuation index and volatility index.
C
Hold
4/4/2014Upgraded
Lexaria Corp. (LXRP) was upgraded to C- from D+ on 4/4/2014 due to an increase in the growth index, valuation index and total return index.
Lexaria Corp. (LXRP) was upgraded to C- from D+ on 4/4/2014 due to an increase in the growth index, valuation index and total return index.
D
Sell
3/20/2014Downgrade
Lexaria Corp. (LXRP) was downgraded to D+ from C- on 3/20/2014 due to a decline in the growth index, valuation index and solvency index. Operating cash flow declined 223.69% from $74.3 to -$91.9, total revenue declined 33.6% from $241.1 to $160.1, and debt to equity increased from 0.61 to 0.63.
Lexaria Corp. (LXRP) was downgraded to D+ from C- on 3/20/2014 due to a decline in the growth index, valuation index and solvency index. Operating cash flow declined 223.69% from $74.3 to -$91.9, total revenue declined 33.6% from $241.1 to $160.1, and debt to equity increased from 0.61 to 0.63.
C
Hold
3/10/2014Upgraded
Lexaria Corp. (LXRP) was upgraded to C- from D+ on 3/10/2014 due to a substantial increase in the volatility index, total return index and valuation index.
Lexaria Corp. (LXRP) was upgraded to C- from D+ on 3/10/2014 due to a substantial increase in the volatility index, total return index and valuation index.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
